AOD-9604 + CJC-1295 + Ipamorelin blend
Also called AOD/CJC/Ipa blend
A three-ingredient combination often discussed for fat loss and body composition. The components have separate, mixed research histories, and the combination has not been tested in people.
Overview
What it is
AOD-9604 is a modified fragment related to human growth hormone. CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue, and ipamorelin is a growth-hormone secretagogue. A "12 mg" label refers to total mass, not 12 mg of each.
How it works
CJC-1295 and ipamorelin act on the body's own growth-hormone release in different ways. AOD-9604 was developed as a fat-metabolism fragment of growth hormone. Raising a hormone level in the lab is not the same as producing a measured health benefit.
What the research shows
In the OPTIONS trial, 502 people received oral AOD-9604 or placebo; there was no significant difference in weight loss at 12 weeks, and the obesity program was discontinued. A long-acting CJC-1295 study measured growth hormone and IGF-1 levels only. Ipamorelin's key early work was in animals. No controlled human trial of the triple combination was identified.
Studied for
- Weight lossAOD-9604, negative trial
- Growth hormone and IGF-1 levelsCJC-1295
- Growth hormone releaseipamorelin, animal
Safety and regulatory status
Safety and side effects
The FDA's AOD-9604 review describes incomplete safety information, including for injection. Using several ingredients at once makes it hard to tell which one caused a side effect.
Regulatory status
Not FDA approved. CJC-1295 "with DAC" and "no DAC" are different substances; results for one should not be applied to the other.
Mixing and dosing reference
Reference information only. Read before using this section.
AOD-9604 + CJC-1295 + Ipamorelin (12 mg Blend) Dosage Protocol
- Vial
- 12 mg total blend 6 mg AOD-9604 + 3 mg CJC-1295 + 3 mg Ipamorelin
- Add diluent
- 3 mL
- Concentration
- 4 mg/mL
- 1 unit (U-100)
- 40 mcg total in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous).
- Typical range
- 0.1–0.2 mL once daily (200–400 mcg AOD / 100–200 mcg CJC / 100–200 mcg Ip).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks.
Standard / Gradual Approach
| Week | Daily Dose | Units (mL) |
|---|---|---|
| Week 1 | 200 mcg AOD / 100 mcg CJC / 100 mcg Ip | 10 units (0.10 mL) |
| Week 2 | 300 mcg AOD / 150 mcg CJC / 150 mcg Ip | 15 units (0.15 mL) |
| Weeks 3–12 | 400 mcg AOD / 200 mcg CJC / 200 mcg Ip | 20 units (0.20 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 0.10 mL daily (200 mcg AOD / 100 mcg CJC / 100 mcg Ip); increase by ~0.05 mL weekly as tolerated.
- Target: 0.20 mL daily (400 mcg AOD / 200 mcg CJC / 200 mcg Ip) by Week 3.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Morning or before bed on an empty stomach; rotate injection sites.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow the exact formulation’s validated use-by and sterile-handling instructions. CDC multi-dose vial guidance concerns contamination risk, not this blend’s chemical shelf life.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Dispose of used syringes in an approved sharps container; follow local disposal regulations.
Important notes
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Best administered on an empty stomach (fasting) for optimal GH release.
Protocol source: PeptideDosages.com
Common questions
Does adding AOD-9604 improve the other two?
The studies reviewed do not show an added benefit.
What is the difference between DAC and no DAC?
DAC changes how the peptide binds to albumin and how long it lasts. They are not interchangeable.
How fast are results?
No dependable timeline has been established for this blend.
Related in Metabolic Health
Sources and further reading (5)
- FDA. AOD-9604: clinical and nonclinical compounding advisory review, 2024.
- Teichman SL, et al. Long-acting CJC-1295 and hormone responses in healthy adults, 2006.
- Raun K, et al. Ipamorelin growth-hormone secretagogue experiments, 1998.
- FDA. CJC-1295 substances: identity and clinical review, 2024.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).